New Delhi: Dr Randeep Guleria, Director, AIIMS Delhi, has said that in India, there are COVID-19 vaccines which are in their final trial stage. Speaking to news agency ANI, he said that he is hopeful that by the end of this month or early next month, emergency use authorization from Indian regulatory authorities with be given to a vaccine, which can then be used to vaccinate the general public.
TOP POINTS
1.Once booster dose is given, vaccine will give good amount of anti-body production & will start giving protection. This will last for many months giving protection for a significant time when numbers will be less. We need to see type of immunity vaccine gives: Dr Randeep Guleria
2.In beginning, vaccine won’t be available in sufficient doses to give to everyone. We need a priority list to see that we vaccinate those who’ve high chances of dying due to Covid. Elderly, people with comorbidities & front line workers should be vaccinated 1st: Dr Randeep Guleria
3.Work is going on at war-footing both at centre & state level for vaccine distribution plan in terms of maintaining cold chain, having appropriate storehouses available, developing strategy, training vaccinators & availability of syringes: Dr Randeep Guleria
4.There is good data available that the vaccines are very safe. Safety & efficacy of vaccine not compromised at all. 70,000-80,000 volunteers given vaccine, no significant serious adverse effects seen. Data shows that in the short term vaccine is safe: Dr Randeep Guleria
5.In India, we now have vaccines which are in their final trial stage. Hopeful that by the end of this month or early next month we should get emergency use authorisation from Indian regulatory authorities to start giving vaccine to public: Dr Randeep Guleria
6.Now, we’ve seen a decline in current wave & I hope this will continue if we are able to have a good COVID19 appropriate behaviour. We’re close to having a big change related to a pandemic if we manage this behaviour for next 3 months: Dr Randeep Guleria
7.Chennai trial case is an incidental finding rather than related to vaccine. When we vaccinate a large number of people, some of them may have some other disease, which may not be related to vaccine: Dr Randeep Guleria, Director, AIIMS Delhi on vaccine impact during Chennai trial
